$GERN Recent Headlines Baker Hughes, Halliburton gain

New Post Public Reply Private Reply Replies (0) Message Board

Jan 15, 2015 at 12:11 PM

$GERN Recent Headlines

Baker Hughes, Halliburton gain on potential merger; Fossil in red 10:07 a.m. Nov. 14, 2014 - Sue Chang
Looming $40 crude and how to vape your way to profits 5:47 a.m. Nov. 14, 2014 - Shawn Langlois
Baker Hughes shares rise on possible buyout 6:02 p.m. Nov. 13, 2014 - Wallace Witkowski
Herbalife shares drop after hours as earnings disappoint 6:58 p.m. Nov. 3, 2014 - Wallace Witkowski
Geron's stock soars after FDA lifts hold on new drug application 7:48 a.m. Nov. 3, 2014 - Tomi Kilgore
Geron's stock jumps 35% premarket after FDA lifts hold on new drug application 7:35 a.m. Nov. 3, 2014 - Tomi Kilgore
FDA places hold on Geren's Imetelstat application 7:25 a.m. March 12, 2014 - MarketWatch.com
Charting the latest market whipsaw 10:59 a.m. Nov. 11, 2013 - Michael Ashbaugh
Oracle active, Geron shares fall after hours 6:06 p.m. Dec. 3, 2012 - Carla Mozee
Geron to discontinue brain-cancer drug development 4:38 p.m. Dec. 3, 2012 - MarketWatch.com
BioTime offers equity stake for Geron assets 8:47 a.m. Oct. 18, 2012 - MarketWatch.com
Monday’s biggest gaining and declining stocks 1:42 p.m. Sept. 10, 2012 - MarketWatch
Geron ends breast cancer study of Imetelstat 7:06 a.m. Sept. 10, 2012 - MarketWatch.com
Stocks to Watch Friday: Splunk, Zumiez, Pandora 3:59 p.m. Aug. 30, 2012 - David B. Wilkerson
Thursday’s biggest gaining and declining stocks 3:31 p.m. Aug. 30, 2012 - MarketWatch
Geron climbs 11% on analyst rating 9:56 a.m. Aug. 30, 2012 - Val Brickates Kennedy
Tuesday’s biggest gaining and declining stocks 5:37 p.m. Nov. 15, 2011 - Kate Gibson
Financial uncertainty nixed Geron stem cell work 2:09 p.m. Nov. 15, 2011 - MarketWatch.com
Stocks to watch Friday: Global Crossing, Clarcor 5:42 a.m. Sept. 30, 2011 - MarketWatch
Court upholds stem-cell research funding: reports 10:46 a.m. July 27, 2011 - Val Brickates Kennedy

Trade-Ideas: Geron (GERN) Is Today's Strong On High Relative Volume Stock 10:03 a.m. Jan. 14, 2015 - TheStreet.com
Geron Corporation (GERN): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report 7:00 a.m. Jan. 12, 2015 - Zacks.com
Seeking Alpha's Biotech Weekly: A Merck Purchase, Spectacular Auspex, And More 4:00 p.m. Dec. 19, 2014 - Seeking Alpha
Geron Enters 2015 On A More Assured Note 3:28 p.m. Dec. 18, 2014 - Seeking Alpha
Market Has Not Yet Noticed Potential in Geron (GERN); Have You? - Tale of the Tape 9:02 a.m. Dec. 17, 2014 - Zacks.com
4 Top Ranked Biotech Stocks that Beat the Market in 2014 - Analyst Blog 11:26 a.m. Dec. 16, 2014 - Zacks.com
Today's Dead Cat Bounce Stock: Geron (GERN) 9:51 a.m. Dec. 11, 2014 - TheStreet.com
Why Geron Corporation (GERN) Stock Might be a Great Pick - Tale of the Tape 8:57 a.m. Dec. 10, 2014 - Zacks.com
Geron (GERN) Stock: Moving Average Crossover Alert - Tale of the Tape 9:47 a.m. Dec. 5, 2014 - Zacks.com
BioTime Harnesses Geron's Stem Cell Technology And Its Founder; Is That Enough To Survive The Biotech Revolution? 10:51 a.m. Dec. 3, 2014 - Seeking Alpha
Geron (GERN) Showing Signs Of A Dead Cat Bounce Today 10:10 a.m. Nov. 26, 2014 - TheStreet.com
Strong On High Relative Volume: Geron (GERN) 10:01 a.m. Nov. 21, 2014 - TheStreet.com
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog 11:23 a.m. Nov. 19, 2014 - Zacks.com
Can the Rally in Geron (GERN) Shares Continue? - Tale of the Tape 8:43 a.m. Nov. 19, 2014 - Zacks.com
Incyte Building Blockbuster Drug One Disease At A Time 2:58 p.m. Nov. 17, 2014 - Investors Business Daily
Geron (GERN) Stock Surges Following Johnson & Johnson Licensing Deal 10:40 a.m. Nov. 17, 2014 - TheStreet.com
Strength Seen in Geron (GERN): Stock Surges 19.5% - Tale of the Tape 9:25 a.m. Nov. 17, 2014 - Zacks.com
Geron Collaborates with J&J for Imetelstat - Analyst Blog 6:00 p.m. Nov. 14, 2014 - Zacks.com
Geron's Short Squeeze Is Here 3:40 p.m. Nov. 14, 2014 - Seeking Alpha
Stock Market Today: Stocks Mixed as Retail Sales Climb, House OKs Keystone Pipeline 3:36 p.m. Nov. 14, 2014 - TheStreet.com

Biotech Stocks Technical Insight -- ARIAD Pharma, Geron, PDL BioPharma, Cytori Therapeutics, and Navidea Biopharma 9:15 a.m. Dec. 18, 2014 - PR Newswire - PRF
Geron Announces Early HSR Clearance for Global Strategic Collaboration with Janssen 7:16 a.m. Dec. 16, 2014 - Thomson Reuters ONE
Geron to Host Analyst and Investor Meeting on December 8 9:31 p.m. Dec. 5, 2014 - Thomson Reuters ONE
Geron Announces Publication of Preclinical Data on Imetelstat Activity in Acute Myelogenous Leukemia 4:16 p.m. Dec. 4, 2014 - Thomson Reuters ONE
Geron to Present at the 26th Annual Piper Jaffray Healthcare Conference 4:16 p.m. Nov. 26, 2014 - Thomson Reuters ONE
Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA 9:00 a.m. Nov. 18, 2014 - PR Newswire - PRF
Geron to Present at the Stifel Healthcare Conference 4:16 p.m. Nov. 14, 2014 - Thomson Reuters ONE
Geron Announces Global Strategic Collaboration with Janssen to Develop and Commercialize Imetelstat 4:16 p.m. Nov. 13, 2014 - Thomson Reuters ONE
Geron Announces Presentations at American Society of Hematology Annual Meeting 9:15 a.m. Nov. 6, 2014 - Thomson Reuters ONE
Geron Announces Removal of Full Clinical Hold on Imetelstat IND 7:31 a.m. Nov. 3, 2014 - Thomson Reuters ONE
Biotech Equities Technical Analysis - ARIAD Pharma, Novavax, Galena Biopharma, Geron, and Celldex Therapeutics 7:40 a.m. Oct. 15, 2014 - PR Newswire - PRF
GERON SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors In Geron Corporation's January 2014 Offering To Contact The Firm 3:00 p.m. Oct. 10, 2014 - PR Newswire - PRF
Biotech Equities Technical Review -- Celldex Therapeutics, Synthetic Biologics, Geron, Catalyst Pharmaceutical Partners, and NPS Pharmaceuticals 8:15 a.m. Sept. 8, 2014 - PR Newswire - PRF
Asterias Biotherapeutics Appoints Two Independent Directors and Announces Completion of Series A Common Stock Distribution 6:00 a.m. Aug. 21, 2014 - PR Newswire - PRF
Geron Corporation Reports Second Quarter 2014 Financial Results 3:06 p.m. Aug. 11, 2014 - Thomson Reuters ONE
Geron to Assume Sponsorship of Myelofibrosis IST and IND 6:30 a.m. Aug. 5, 2014 - Thomson Reuters ONE
Biotech Stocks Technical Data -- MannKind, ARIAD Pharma, Galena Biopharma, Geron, and Peregrine Pharma 8:00 a.m. Aug. 1, 2014 - PR Newswire - PRF
Geron Announces Conference Call to Discuss Second Quarter 2014 Financial Results 6:31 a.m. July 30, 2014 - Thomson Reuters ONE
Stock Watchout on Biotech Industry -- Research on ARIAD Pharma, Geron, Seattle Genetics, and Sarepta Therapeutics 6:30 a.m. June 26, 2014 - PR Newswire - PRF
Sales, Clinical Hold Removal, Trial Initiations, and Committee Recommendations - Analyst Notes on Geron, Zalicus, Northwest Biotherapeutics, Progenics and TG Therapeutics 4:30 a.m. June 17, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...